Abstract Purpose: To assess the long-term anatomical and functional findings in patients with symptomatic vitreomacular traction (VMT), with or without full thickness macular hole (FTMH), after eye treatment with intravitreal ocriplasmin injection (IOI). Methods: This longitudinal case series includes 51 eyes from 51 symptomatic patients with VMT (<800 μm) who received a single IOI (Jetrea® 0.125 mg); 21 cases with an FTMH (<400 μm) were included. Best-corrected visual acuity (BCVA) and optical coherence tomography findings were recorded before IOI, and 1 day to 24 months thereafter. Data are presented as mean ± standard deviation. Results: Mean adhesion size before injection was 345 ± 146 μm. In 34 eyes (67%), complete release of VMT was...
This retrospective quality control study aimed at comparing resolution in patients treated with intr...
PURPOSE: The purpose is to evaluate functional changes after ocriplasmin injection to treat vitreoma...
Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treatment...
To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacu...
Purpose: To report the clinical course of our first 7 consecutive patients treated with intravitreal...
Background: To evaluate the functional recovery of patients with symptomatic vitreomacular traction ...
AbstractPurpose: To evaluate success with intravitreal injection of ocriplasmin in releasing symptom...
Purpose: To compare the functional and morphologic outcome of patients with vitreomacular traction (...
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer ...
PURPOSE: To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with v...
Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravit...
Joanna DaCosta,1,2 Saad Younis1 1The Western Eye Hospital, Imperial College Healthcare National Heal...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
BACKGROUND AND OBJECTIVE: To determine early evolution of the vitreomacular interface and clinical e...
PURPOSE: To evaluate the anatomical and functional outcomes with ocriplasmin in patients with vitreo...
This retrospective quality control study aimed at comparing resolution in patients treated with intr...
PURPOSE: The purpose is to evaluate functional changes after ocriplasmin injection to treat vitreoma...
Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treatment...
To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacu...
Purpose: To report the clinical course of our first 7 consecutive patients treated with intravitreal...
Background: To evaluate the functional recovery of patients with symptomatic vitreomacular traction ...
AbstractPurpose: To evaluate success with intravitreal injection of ocriplasmin in releasing symptom...
Purpose: To compare the functional and morphologic outcome of patients with vitreomacular traction (...
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer ...
PURPOSE: To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with v...
Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravit...
Joanna DaCosta,1,2 Saad Younis1 1The Western Eye Hospital, Imperial College Healthcare National Heal...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
BACKGROUND AND OBJECTIVE: To determine early evolution of the vitreomacular interface and clinical e...
PURPOSE: To evaluate the anatomical and functional outcomes with ocriplasmin in patients with vitreo...
This retrospective quality control study aimed at comparing resolution in patients treated with intr...
PURPOSE: The purpose is to evaluate functional changes after ocriplasmin injection to treat vitreoma...
Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treatment...